Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors
10.3760/cma.j.issn.1673-422X.2010.12.019
- VernacularTitle:伊马替尼治疗胃肠道间质瘤的继发性耐药机制
- Author:
Chuan LIU
;
Ning WANG
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stromal tumours;
Drug resistance,neoplasm
- From:
Journal of International Oncology
2010;37(12):936-939
- CountryChina
- Language:Chinese
-
Abstract:
Imatinib is an effective tyrosine kinase inhibitor, used in the treatment of advanced or inoperable gastrointestinal stromal tumors. Despite its efficacy, resistance is often developed among a portion of patients. Resistance to imatinib can be divided into primary and secondary resistance, with the latter becoming the focus of many recent researches. Research on the mechanisms of secondary resistance may lead to the identification of novel therapeutic strategies.
